首页> 美国卫生研究院文献>Bioengineering Translational Medicine >Evaluation of receptor‐ligand mechanisms of dual‐targeted particles to an inflamed endothelium
【2h】

Evaluation of receptor‐ligand mechanisms of dual‐targeted particles to an inflamed endothelium

机译:评价双靶标颗粒对内皮发炎的受体配体机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vascular‐targeted carriers (VTCs) are designed as leukocyte mimics, decorated with ligands that target leukocyte adhesion molecules (LAMs) and facilitate adhesion to diseased endothelium. VTCs require different design considerations than other targeted particle therapies; adhesion of VTCs in regions with dynamic blood flow requires multiple ligand‐receptor (LR) pairs that provide particle adhesion and disease specificity. Despite the ultimate goal of leukocyte mimicry, the specificity of multiple LAM‐targeted VTCs remains poorly understood, especially in physiological environments. Here, we investigate particle binding to an inflamed mesentery via intravital microscopy using a series of particles with well‐controlled ligand properties. We find that the total number of sites of a single ligand can drive particle adhesion to the endothelium, however, combining ligands that target multiple LR pairs provides a more effective approach. Combining sites of sialyl Lewis A (sLeA) and anti‐intercellular adhesion molecule‐1 (aICAM), two adhesive molecules, resulted in ∼3–7‐fold increase of adherent particles at the endothelium over single‐ligand particles. At a constant total ligand density, a particle with a ratio of 75% sLeA: 25% aICAM resulted in more than 3‐fold increase over all over other ligand ratios tested in our in vivo model. Combined with in vivo and in silico data, we find the best dual‐ligand design of a particle is heavily dependent on the surface expression of the endothelial cells, producing superior adhesion with more particle ligand for the lesser‐expressed receptor. These results establish the importance of considering LR‐kinetics in intelligent VTC ligand design for future therapeutics.
机译:靶向血管的载体(VTC)被设计为白细胞模拟物,并饰有靶向白细胞粘附分子(LAM)并促进与病变内皮细胞粘附的配体。 VTC与其他目标粒子疗法相比需要不同的设计考虑; VTC在具有动态血流区域的粘附需要多个配体-受体(LR)对,以提供颗粒粘附和疾病特异性。尽管白细胞模拟的最终目标是,但针对多个LAM靶向VTC的特异性仍然知之甚少,尤其是在生理环境中。在这里,我们使用一系列具有良好控制的配体特性的颗粒,通过活体显微镜研究了颗粒与发炎的肠系膜的结合。我们发现单个配体的位点总数可以驱动颗粒粘附到内皮,但是,结合靶向多个LR对的配体提供了一种更有效的方法。唾液酸化的Lewis A(sLe A )和抗细胞间粘附分子-1(aICAM)这两个粘附分子的结合位点导致内皮细胞粘附颗粒的数量增加了约3–7倍配体颗粒。在恒定的总配体密度下,比例为75%sLe A :25%aICAM的颗粒比我们在体内模型中测试的所有其他配体比率提高了三倍以上。结合体内和计算机模拟数据,我们发现颗粒的最佳双配体设计在很大程度上取决于内皮细胞的表面表达,与表达较少的受体的更多颗粒配体产生优异的粘附性。这些结果确立了在智能VTC配体设计中考虑LR运动动力学以用于未来治疗的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号